RNA-Based Therapies for Axonal Degeneration

Abstract

Axonal degeneration is a pathophysiological hallmark underlying many neurodegenerative diseases, contributing to progressive neurological dysfunction and disability. Traditional management strategies have focused predominantly on symptomatic relief rather than disease modification. Recent advances in molecular neuroscience and gene therapy have enabled the development of RNA-based therapeutics, offering targeted and potentially disease-modifying interventions for axonal degeneration. This article reviews the epidemiology, molecular mechanisms, clinical features, diagnostic approaches, and established as well as emerging management strategies for axonal degeneration, with a focus on the latest evidence regarding RNA-based therapies. The review also highlights guideline recommendations, practical considerations, and future perspectives relevant to clinical practice.

Introduction

Axonal degeneration is a central process in a broad spectrum of neurological diseases, including amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), hereditary neuropathies, and traumatic nerve injuries. Axons, the long projections of neurons responsible for transmitting electrical impulses, are vulnerable to metabolic, inflammatory, and genetic insults. Historically, therapeutic strategies have provided limited benefits in halting or reversing axonal loss. The recent advent of RNA-based therapeutics including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and messenger RNA (mRNA)-modifying agents has catalyzed a paradigm shift in the potential management of axonal degeneration. This review provides an in-depth examination of the scientific basis, clinical evidence, and future prospects of RNA-based therapies in this context, targeting healthcare professionals and researchers seeking to translate cutting-edge science into clinical practice.

Epidemiology / Disease Burden

Axonal degeneration is implicated in a wide range of neurological disorders, affecting millions worldwide. In ALS, for instance, axonal loss leads to progressive motor dysfunction in approximately 2 per 100,000 individuals annually. In MS, chronic axonal degeneration underlies irreversible disability, with global prevalence estimates reaching over 2.8 million people. Hereditary neuropathies, such as Charcot-Marie-Tooth disease, also display prominent axonal pathology. The socioeconomic burden is substantial, encompassing direct healthcare costs, loss of productivity, and reduced quality of life. Early intervention targeting axonal integrity is therefore a critical unmet medical need.

Pathophysiology

Axonal degeneration is driven by a complex interplay of molecular mechanisms, which may be categorized into Wallerian degeneration (post-injury), dying-back neuropathy (distal-to-proximal loss), and programmed axonal death. Key pathways involve calcium dysregulation, mitochondrial dysfunction, impaired axonal transport, oxidative stress, and activation of SARM1-mediated self-destruction. Genetic mutations such as those affecting mitofusin 2, neurofilament light chain, or SOD1 may disrupt axonal homeostasis. Importantly, non-cell autonomous mechanisms, including glial cell dysfunction and neuroinflammation, further exacerbate axonal vulnerability. Understanding these mechanisms has been pivotal in identifying molecular targets for RNA-based therapeutic intervention.

Risk Factors

Risk factors for axonal degeneration are multifactorial and disease-specific. Genetic predisposition plays a significant role in hereditary neuropathies and familial neurodegenerative disorders. Environmental factors, such as toxins, infections, and metabolic derangements (e.g., diabetes), contribute to acquired axonopathies. Age, chronic inflammation (as in MS), and traumatic injuries are additional risk modifiers. Importantly, certain gene mutations (e.g., in SOD1, MFN2, PMP22) have been directly implicated in axonal vulnerability, underscoring the relevance of targeted genetic and RNA-based interventions.

Clinical Features

Axonal degeneration manifests with a spectrum of neurological deficits, depending on the affected neuronal pathways. Motor neuron pathology typically results in progressive weakness, muscle atrophy, and fasciculations, as seen in ALS. Sensory axonopathy leads to numbness, paresthesia, and impaired proprioception, characteristic of peripheral neuropathies. In central nervous system disorders such as MS, axonal loss contributes to spasticity, ataxia, and cognitive decline. Chronic progression, stepwise deterioration, and incomplete recovery following relapses are clinical hallmarks of ongoing axonal damage.

Diagnosis

Diagnosis of axonal degeneration integrates clinical assessment, electrophysiological studies, neuroimaging, and molecular diagnostics. Nerve conduction studies (NCS) and electromyography (EMG) are instrumental in differentiating axonal from demyelinating neuropathies. Advanced MRI techniques, including diffusion tensor imaging (DTI), enable visualization of axonal tract integrity in vivo. Biomarkers such as neurofilament light chain, detectable in cerebrospinal fluid and serum, offer sensitive indicators of axonal injury. Genetic testing is essential in hereditary cases, guiding both prognosis and potential eligibility for RNA-targeted therapies.

Treatment & Management

Traditional management of axonal degeneration has centered on symptom control, physical rehabilitation, and prevention of complications. Disease-modifying therapies are limited, particularly for non-inflammatory axonopathies. Immunomodulatory agents benefit select conditions (e.g., MS), but do not directly target axonal survival. Recent pharmacological advances such as the use of neurotrophic factors, antioxidants, and agents stabilizing axonal cytoskeleton have yielded modest benefits. Multidisciplinary care, including neurology, rehabilitation, and supportive services, remains the cornerstone of comprehensive management.

Recent Advances / Emerging Therapies

RNA-based therapies represent a transformative frontier in the management of axonal degeneration. Antisense oligonucleotides (ASOs), exemplified by nusinersen in spinal muscular atrophy (SMA), modulate the splicing of pre-mRNA to enhance survival motor neuron (SMN) protein production, effectively slowing disease progression. In ALS, ASOs targeting SOD1 and C9orf72 mutations have demonstrated safety and target engagement in early clinical trials, with ongoing studies evaluating clinical efficacy. Small interfering RNAs (siRNAs) offer allele-specific silencing, reducing toxic protein accumulation in inherited neuropathies. mRNA therapies, currently in preclinical development, aim to restore or supplement deficient proteins critical for axonal maintenance. Delivery strategies including intrathecal administration, lipid nanoparticles, and viral vectors are being refined to enhance CNS penetrance and minimize off-target effects. Collectively, these modalities offer precision medicine approaches with the potential to modify disease trajectory and improve neurological outcomes.

Guideline Recommendations

Clinical guidelines for RNA-based therapies in axonal degeneration are evolving in parallel with emerging evidence. For SMA, consensus guidelines endorse the use of ASOs (nusinersen, risdiplam) as standard of care. In ALS and hereditary neuropathies, RNA-based therapies are recommended within clinical trial settings pending robust efficacy and long-term safety data. Expert panels emphasize the importance of genetic testing for accurate diagnosis, patient stratification, and therapy selection. Ongoing surveillance for adverse effects, including neuroinflammation and immune responses, is recommended for all patients receiving RNA-based interventions. Multidisciplinary collaboration and patient education are integral to optimizing clinical outcomes.

Conclusion

Axonal degeneration remains a major contributor to neurological disability across diverse disease entities. The emergence of RNA-based therapies marks a significant milestone, offering targeted, mechanism-based interventions with the potential to alter disease course. While challenges remain regarding delivery, long-term safety, and cost, the accumulating clinical evidence supports a growing role for RNA therapeutics in the management of axonal degeneration. Continued research, interdisciplinary collaboration, and adherence to evolving guidelines will be essential to realize the full therapeutic potential of these innovative modalities for patients with neurodegenerative diseases.